Possibilities and Limitations of an Three-dimensional Bone Marrow Model for the Prediction of Clinical Responses in Patients with Relapsed Multiple Myeloma

Overview

Journal Haematologica

Specialty Hematology

Date 2019 Apr 21

PMID 31004023

Citations 4

Authors

Maaike V J Braham

Jacqueline Alblas

Wouter J A Dhert

F Cumhur Oner

Monique C Minnema

Affiliations

Soon will be listed here.

Citing Articles

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model.

van Nieuwenhuijzen N, Cuenca M, Abbink L, Jak M, Peperzak V, Minnema M EJHaem. 2024; 5(1):141-146.

PMID: 38406516 PMC: 10887349. DOI: 10.1002/jha2.824.

A synthetic human 3D lymphoid model enhancing B-cell survival and functional differentiation.

Braham M, van Binnendijk R, Buisman A, Mebius R, Wit J, van Els C iScience. 2023; 26(1):105741.

PMID: 36590159 PMC: 9794978. DOI: 10.1016/j.isci.2022.105741.

Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine-Are We There Yet?.

Lourenco D, Lopes R, Pestana C, Queiros A, Joao C, Carneiro E Int J Mol Sci. 2022; 23(21).

PMID: 36361677 PMC: 9657251. DOI: 10.3390/ijms232112888.

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression.

Maiso P, Mogollon P, Ocio E, Garayoa M Cancers (Basel). 2021; 13(11).

PMID: 34067236 PMC: 8196907. DOI: 10.3390/cancers13112542.

References

Jakubikova J, Cholujova D, Hideshima T, Gronesova P, Soltysova A, Harada T . A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016; 7(47):77326-77341. PMC: 5357212. DOI: 10.18632/oncotarget.12643. View

Quach H, Ritchie D, Stewart A, Neeson P, Harrison S, Smyth M . Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2009; 24(1):22-32. PMC: 3922408. DOI: 10.1038/leu.2009.236. View

Kirshner J, Thulien K, Martin L, Debes Marun C, Reiman T, Belch A . A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood. 2008; 112(7):2935-45. DOI: 10.1182/blood-2008-02-142430. View

Belloni D, Heltai S, Ponzoni M, Villa A, Vergani B, Pecciarini L . Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment. Haematologica. 2018; 103(4):707-716. PMC: 5865414. DOI: 10.3324/haematol.2017.167486. View

Majumder M, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B . Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget. 2017; 8(34):56338-56350. PMC: 5593565. DOI: 10.18632/oncotarget.17630. View

Sonneveld P, Broijl A . Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016; 101(8):995. PMC: 4967579. DOI: 10.3324/haematol.2016.148882. View

Reagan M, Mishima Y, Glavey S, Zhang Y, Manier S, Lu Z . Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood. 2014; 124(22):3250-9. PMC: 4239334. DOI: 10.1182/blood-2014-02-558007. View

Holstein S, McCarthy P . Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. Drugs. 2017; 77(5):505-520. PMC: 5705939. DOI: 10.1007/s40265-017-0689-1. View

Kumar S, Rajkumar V, Kyle R, van Duin M, Sonneveld P, Mateos M . Multiple myeloma. Nat Rev Dis Primers. 2017; 3:17046. DOI: 10.1038/nrdp.2017.46. View

10.

Braham M, Minnema M, Aarts T, Sebestyen Z, Straetemans T, Vyborova A . Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. Oncoimmunology. 2018; 7(6):e1434465. PMC: 5980416. DOI: 10.1080/2162402X.2018.1434465. View

11.

Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S . Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016; 175(2):252-264. PMC: 5096152. DOI: 10.1111/bjh.14213. View

12.

Silva A, Silva M, Sudalagunta P, Distler A, Jacobson T, Collins A . An Platform for the Prediction of Clinical Response in Multiple Myeloma. Cancer Res. 2017; 77(12):3336-3351. PMC: 7819642. DOI: 10.1158/0008-5472.CAN-17-0502. View

13.

Kimlin L, Kassis J, Virador V . 3D in vitro tissue models and their potential for drug screening. Expert Opin Drug Discov. 2013; 8(12):1455-66. DOI: 10.1517/17460441.2013.852181. View

14.

Braham M, Deshantri A, Minnema M, Oner F, Schiffelers R, Fens M . Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma. Int J Nanomedicine. 2018; 13:8105-8118. PMC: 6278842. DOI: 10.2147/IJN.S184262. View

15.

de la Puente P, Muz B, Gilson R, Azab F, Luderer M, King J . 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials. 2015; 73:70-84. PMC: 4917006. DOI: 10.1016/j.biomaterials.2015.09.017. View